The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sivolap Yu.P.

Sechenov First Moscow State Medical University (Sechenov University)

Systematics and treatment of anxiety disorders

Authors:

Sivolap Yu.P.

More about the authors

Read: 25833 times


To cite this article:

Sivolap YuP. Systematics and treatment of anxiety disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):121‑127. (In Russ.)
https://doi.org/10.17116/jnevro2020120071121

Recommended articles:
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Hysterical diso­rders in patients with hema­tological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):71-78
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Atte­ntion defi­cit hype­ractivity diso­rder: pharmacotherapy in special situations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):59-65
Features of arte­rial hype­rtension in indi­viduals with anxiety diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):44-51
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411

References:

  1. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-335. 
  2. Schatzberg A, DeBattista C. Schatzberg’s manual of clinical psychopharmacology. Ninth Edition. Washington: American Psychiatric Association Publishing; 2019.
  3. Semple D, Smyth R. Oxford handbook of psychiatry. Fourth Edition. Oxford: Oxford University Press; 2019.
  4. ICD-10 Version: 2019. https://icd.who.int/browse10/2019/en#/F40
  5. ICD-11 for Mortality and Morbidity Statistics. (Version: 04/2019). https://icd.who.int/browse11/l-m/en
  6. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Fifth Edition. Washington, D.C.: American Psychiatric Association; 2013.
  7. Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: An evidence-based treatment review. Review Expert Opin Pharmacother. 2018;19(10):1057-1070. https://doi.org/10.1080/14656566.2018.1491966
  8. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107. 
  9. Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The German guidelines for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):363-373.  https://doi.org/10.1007/s00406-014-0563-z
  10. Taylor DM, Barnes TRE, Young AH. The maudsley prescribing guidelines in psychiatry. Thirteenth Edition. Chichester: Wiley Blackwell; 2018.
  11. National Institute for Health and Care Excellence (2011, updated 2019). Generalized anxiety disorder and panic disorder in adults: management. NICE guidance. Clinical guideline [CG113]. https://www.nice.org.uk/guidance/cg113
  12. Bandelow B. Current and novel psychopharmacological drugs for anxiety disorders. Adv Exp Med Biol. 2020;1191:347-365.  https://doi.org/10.1007/978-981-32-9705-0_19
  13. Jakubovski EJA, Nasir M, Müller-Vahl K, Bloch MH. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depress Anxiety. 2019;36(3):198-212.  https://doi.org/10.1002/da.22854
  14. Casacalenda N, Boulenger JP. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Can J Psychiatry. 1998;43(7):722-730.  https://doi.org/10.1177/070674379804300707
  15. Feighner JP, Aden GC, Fabre LF, Rickels K, Smith WT. Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA. 1983;249(22):3057-3064. https://doi.org/10.1001/jama.1983.03330460039029
  16. Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K, Kaplan M, Amsterdam JD. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry. 1987;44(10):862-826.  https://doi.org/10.1001/archpsyc.1987.01800220024005
  17. Van Marwijk H, Allick G, Wegman F, Bax A, Riphagen II. Alprazolam for depression. Cochrane Database Syst Rev. 2012;7:CD007139. https://doi.org/10.1002/14651858.CD007139.pub2
  18. DiMauro J, Domingues J, Fernandez G, Tolin DF. Long-term effectiveness of CBT for anxiety disorders in an adult outpatient clinic sample: A follow-up study. Behav Research Ther. 2013;51(2):82-86.  https://doi.org/10.1016/j.brat.2012.10.003
  19. El-Guebaly N, Sareen J, Stein MB. Are there guidelines for the responsible prescription of benzodiazepines? Can J Psychiatry. 2010;55(11):709-714.  https://doi.org/10.1177/070674371005501104
  20. Stahl SM. Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 2002;63(9):756-767.  https://doi.org/10.4088/jcp.v63n0901
  21. Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: A meta-analytic review. Expert Opin Pharmacother. 2018;19(8):883-894.  https://doi.org/10.1080/14656566.2018.1472767
  22. Storage S, Ravindranath D, Abelson J. The Anxious Patient. In: Clinical Manual of Emergency Psychiatry (edited by Michelle B. Riba, Divy Ravindranath, Gerald S. Winder). Second Edition. Arlington: American Psychiatric Association Publishing; 2016.
  23. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: A systematic review and meta-analysis. Review Psychother Psychosom. 2013;82(6):355-362.  https://doi.org/10.1159/000353198
  24. Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):187399-187399. https://doi.org/10.1001/jamanetworkopen.2018.7399
  25. Balon R, Starcevic V, Silberman E, Cosci F, Dubovsky S, Fava GA, Nardi AE, Rickels K, Salzman C, Shader RI, Sonino N. The rise and fall and rise of benzodiazepines: A return of the stigmatized and repressed. Braz J Psychiatry. 2020;42(3):243-244.  https://doi.org/10.1590/1516-4446-2019-0773
  26. Aouizerate B, Martin-Guehl C, Tignol J. Neurobiology and pharmacotherapy of social phobia. Encephale. 2004;30(4):301-313.  https://doi.org/10.1016/s0013-7006(04)95442-5
  27. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996;39(2):115-121.  https://doi.org/10.1016/0165-0327(96)00030-4
  28. Comer JS, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry. 2011;168(10):1057-1065. https://doi.org/10.1176/appi.ajp.2011.11010087
  29. Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259-276.  https://doi.org/10.2147/DDDT.S89485
  30. Bailey MA, Saraswatula A, Dale G, Softley L. Paediatric sedation for imaging is safe and effective in a district general hospital. Br J Radiol. 2016;89(1061):20150483. https://doi.org/10.1259/bjr.20150483
  31. Hartz I, Skurtveit S, Steffenak AK, Karlstad Ø, Handal M. Psychotropic drug use among 0—17 year olds during 2004—2014: a nationwide prescription database study. BMC Psychiatry. 2016;16:12.  https://doi.org/10.1186/s12888-016-0716-x
  32. Durham RC. Treatment of generalized anxiety disorder. Psychiatry. 2007;6(5):183-187.  https://doi.org/10.1016/j.mppsy.2007.03.003
  33. Maron E, Nutt D. Biological markers of generalized anxiety disorder. Dialogues Clin Neurosci. 2017;19(2):147-158. 
  34. Griebel G, Holmes A. 50 Years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013;12(9):667-687.  https://doi.org/10.1038/nrd4075

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.